^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Bladder Cancer
    Drug:belzupacap sarotalocan (AU-011) (Reactive oxygen species stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Aura Biosciences Press Release
    Title:

    Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

    Published date:
    06/30/2022
    Excerpt:
    Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for belzupacap sarotalocan (AU-011), Aura’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).